Clinical guide balances GLP-1 receptor agonist benefits with individualized safety for diverse populations

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes, obesity, and various metabolic and cardiorenal conditions. As their use expands to younger, healthier, and more diverse patient groups, clinicians face a growing need for comprehensive guidance that effectively balances the significant therapeutic benefits with individualized safety considerations. Current standard-of-care protocols often lack the nuanced approach required for these broader populations, particularly concerning the practical management of adverse effects and fostering patient-centered care. This review addresses this critical gap by providing a structured framework for informed decision-making.

This review synthesizes current evidence regarding GLP-1 receptor agonists, focusing on their physiological mechanisms, clinical indications, and practical safety considerations. The authors developed a structured, clinically oriented approach for monitoring and managing adverse effects, with a particular emphasis on gastrointestinal intolerance. This includes an algorithm designed for early symptom management. Furthermore, the review outlines effective communication strategies aimed at supporting shared decision-making, reducing treatment-related stigma, and ensuring therapeutic plans are aligned with individual patient goals and preferences. The methodology involved a comprehensive synthesis of existing literature to create this practical guide.

The review provides a comprehensive framework for clinicians navigating the expanding use of GLP-1 receptor agonists. It details the physiological mechanisms underlying their efficacy in glycemic control, weight loss, and cardiovascular protection, while also outlining their established clinical indications across type 2 diabetes, obesity, and related cardiometabolic conditions. A significant focus is placed on practical safety considerations, particularly the management of gastrointestinal intolerance, which is a common reason for treatment discontinuation. > The guide includes a specific algorithm for the early management of GLP-1 RA-associated gastrointestinal symptoms, aiming to improve patient adherence and tolerability. Beyond adverse effect management, the review emphasizes the importance of communication strategies to facilitate shared decision-making, ensuring patients are fully informed about benefits and risks. It also addresses methods to reduce stigma associated with conditions like obesity and the use of pharmacotherapy, promoting a more patient-centered approach to care. This synthesis aims to empower clinicians to deliver safe, informed, and highly individualized GLP-1 RA therapy.